Last Updated on December 21, 2024 by The Health Master
USFDA approval
Lupin Pharmaceuticals has achieved a significant milestone with the recent United States Food and Drug Administration approval (USFDA approval) for its generic version of Alphagan P Ophthalmic Solution.
This approval paves the way for Lupin to market a generic equivalent of the brand-name drug, Brimonidine Tartrate Ophthalmic Solution, 0.1%.
A Generic Alternative for Glaucoma and Ocular Hypertension
Brimonidine Tartrate Ophthalmic Solution is a valuable medication used to treat open-angle glaucoma and ocular hypertension.
It works by reducing the elevated intraocular pressure (IOP) in the eye.
By providing a generic alternative to Alphagan P, Lupin is making this essential treatment more accessible to patients.
Manufacturing in India
Lupin’s Pithampur facility in India will be responsible for manufacturing the generic Brimonidine Tartrate Ophthalmic Solution.
This demonstrates Lupin’s commitment to providing high-quality medications while also contributing to the Indian pharmaceutical industry’s growth.
Market Potential and Sales Estimates
The generic Brimonidine Tartrate Ophthalmic Solution market in the United States is estimated to be worth USD 178.5 million annually, based on IQVIA data for the period ending June 2024.
This indicates a substantial market opportunity for Lupin’s new product.
Key Points:
- Lupin has received USFDA approval for generic Brimonidine Tartrate Ophthalmic Solution.
- The drug is used to treat open-angle glaucoma and ocular hypertension.
- It will be manufactured at Lupin’s Pithampur facility in India.
- The generic market for this drug is estimated to be worth USD 178.5 million annually.
With the USFDA approval, Lupin is poised to offer a cost-effective alternative to Alphagan P, benefiting patients and healthcare providers alike.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for Glycopyrrolate Oral Solution
USFDA approval granted for blockbuster drug for Cancer treatment
USFDA approval granted for Valbenazine Capsules
USFDA approval granted for Trazodone tablets
Revamping the Indian Pharma Supply Chain: A Comprehensive Report
Supreme Court stays notification omitting Misleading Advertisement Rule
Drug recall: Aurobindo, Glenmark, FDC recall drugs due to Quality Issues
CDSCO must maintain a registry of all Brand Name of Drugs: Dr BR Jagashetty
Jan Aushadhi: A Lifeline for Affordable Healthcare in India
Pharma Industry seeks more time to implement Revised Schedule M
Govt notifies Delhi Drug Inspector Recruitment Rules
156 Drugs banned in India: Download list
Drug alert: 70 drug samples declared as NSQ in July 2024
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
